Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — ABGSC Seminar - Autoimmunity, Transplantation & Inflammation 2024
14 slides from Nykode Therapeutics Asa's conference presentation, Jun 11, 2024
Slide 1: ABGSC Seminar - Autoimmunity, Transplantation & Inflammation
ABGSC Seminar - Autoimmunity, Transplantation & Inflammation June 11, 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Global leader in antigen presenting cell (APC)-targeted immunotherapy technology
Global leader in antigen presenting cell (APC)-targeted immunotherapy technology NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$500M1) Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases Bro
Slide 4: Broad pipeline targeting early to late-stage cancer treatment
Broad pipeline targeting early to late-stage cancer treatment Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 Finalize enrolment Pt 1 HPV16+ cervical cancer C-02, C-04 (Q4 2024) 2 Dose level VB10.16 HPV16+ head and neck cancer C-03 recommendation (H2 2024) 2
Slide 5: Strong rationale for moving into Immune Tolerance
Strong rationale for moving into Immune Tolerance Autoimmune disease Inverse vaccines present The field is gaining therapy relies on broadly a new promising avenue traction and partnership immunosuppressive with potential for long- interest from major therapies which leaves a lasting efficacy and pl
Slide 6: Modular design with multiple targeting and 4th modules for antigen-specific immune tolerance
Modular design with multiple targeting and 4th modules able to ensure antigen-specific immune tolerance Module 1: Multiple targeting units for receptors on tolerizing APCs identified including natural ligands and other targeting molecules Module 3: Auto-antigens or allergens known to elicit unwanted
Slide 7: Induction of antigen specific tolerance by targeting epitopes to tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with Effector DNA plasmid B cell vaccine Tol CD4+ Treg APC CD4+ Treg Tol APC Effector Effector T cell T
Slide 8: APC targeting is required for effective disease protection
APC targeting is required for effective disease protection EAE MODEL 30 µg 3 µg 0.3 µg Tol. TV004 TV042 5 5 APC 5 PBS 4 4 4 EAE score EAE score EAE score 3 3 3 2 2 2 1 1 1 0 0 0 6 8 10 12 14 16 18 20 22 24 26 28 6 8 10 12 14 16 18 20 22 24 26 28 6 8 10 12 14 16 18 20 22 24 26 28 MOG MOG Days post EA
Slide 9: Vaccibody delivers Ag-specific suppression of EAE
Vaccibody delivers Ag-specific suppression of EAE EAE MODEL – OVA CONTROL TV004 TV043 OVA control 5 4 MOG OVA EAE score (27-63) (323-339) 3 TV004 2 TV043 Daily clinical scores PBS day -3 day 0 day 28 1 day -7 EAE Termination 0 induction i.v. 6 8 10 12 14 16 18 20 22 24 26 28 Pertussis toxin Days pos
Slide 10: Vaccibody vaccine prevents EAE disease in an early therapeutic setting
Vaccibody vaccine prevents EAE disease in an early therapeutic setting EAE MODEL – EARLY THERAPEUTIC DELIVERY TV004 5 ✱✱✱ TV004 100 4 PBS 80 EAE score AUC (5-28) MOG (27-63) 3 60 2 40 Daily clinical scores (5-28) 1 20 day 28 0 0 Termination EAE 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 PBS TV004 induc
Slide 11: Advancements highlighting the unique benefits of Nykode's APC-targeted platform
Advancements highlighting the unique benefits of Nykode’s APC-targeted platform for autoimmunity treatment Demonstrated Protection 2. Drug Loading Dependent on APC and Delivery - R&D targeting 3. Partnerships Versatile Format Nykode's inverse vaccines The effects were shown to The potent tolerizing
Slide 12: Autoimmune indications are an attractive platform expansion category
Autoimmune indications are an attractive platform expansion category Scientific Greenfield opportunity of APC- therapeutic Attractive Ability to add targeted vaccines to opportunity with commercial sizeable commercial drive antigen- broad range of opportunity; Top 10 potential to specific immune pot
Slide 13: Nykode's successful business model validated and ready to accelerate development
Nykode’s successful business model validated and ready to accelerate development in autoimmune diseases Expand candidate to all addressable Expansion into the First in patients broad potential of house candidate autoimmune disorders, towards the allergies and organ Clinical market transplantation Po
Slide 14: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Agnete Fredriksen Chief Scientific Officer & Business Development abfredriksen@nykode.com Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential
Nykode Therapeutics — ABGSC Seminar - Autoimmunity, Transplantation & Inflammation 2024 on 6ix